Noom Medical Leadership and Credentials: An Independent Review

Who Leads Noom Clinically?

Noom's clinical team is anchored by a Chief Medical Officer role and a network of contracted telehealth physicians. The company named Dr. Andres Acosta, a Mayo Clinic-trained gastroenterologist and obesity medicine specialist, as CMO in 2024. His research background includes published work on gut-brain hormone signaling and body weight phenotyping.

The CMO's Research Profile

Dr. Acosta has authored peer-reviewed work on GLP-1 receptor biology and obesity subtypes. His 2022 publication in the journal Obesity proposed a precision medicine framework for anti-obesity medications. That published record lends scientific credibility to Noom's shift toward GLP-1 integration, though it does not independently validate Noom's internal protocols.

Telehealth Physician Network

Beyond the CMO, Noom Med relies on a distributed network of U.S.-licensed physicians who conduct asynchronous intake reviews. Patients submit health history forms; a physician reviews the file and issues or denies a prescription. This model is legal under current FDA telehealth rules and mirrors the approach used by competitors such as Ro and Hims & Hers, but it limits the depth of any single clinical encounter. A 2023 JAMA Internal Medicine commentary noted that asynchronous prescribing for obesity medications "warrants standardized clinical decision criteria to minimize inappropriate prescribing" [1].

Coaching Staff Qualifications

Noom's coaches are not licensed dietitians or therapists by default. The company states that coaches complete an internal certification program. No independent accrediting body, such as the National Board for Health and Wellness Coaching (NBHWC), is required for Noom coaches. This gap matters clinically because patients with complex metabolic histories may receive guidance from staff who lack formal clinical training.

What Does the Published Evidence Actually Show?

Noom's own peer-reviewed evidence base is thin but not absent. The most-cited study is a retrospective analysis published in 2020.

The Natarajan 2020 Study

Natarajan et al. (2020) analyzed 43,569 Noom users over 18 weeks and found that 77.9% of completers lost weight, with a mean loss of 7.1 kg among those who logged food for more than half the program days [2]. The study appeared in Scientific Reports and was co-authored by Noom employees, which introduces a conflict of interest. The population was self-selected, lacked a true randomized control arm, and relied entirely on app-reported data. These are meaningful limitations.

GLP-1 Trial Evidence Noom Med Borrows From

Noom Med prescribes semaglutide (brand name Wegovy) and, in some cases, tirzepatide (Zepbound). The efficacy data for these drugs comes from independent manufacturer-funded trials, not Noom's own research.

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [3]. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [4]. Noom Med's clinical outcomes depend entirely on these drug effects. The app-based behavioral component may support adherence, but no published RCT has tested Noom Med's combined drug-plus-coaching model specifically.

What the Absence of Noom-Specific GLP-1 Data Means

Any telehealth platform that prescribes GLP-1 agonists can point to STEP-1 and SURMOUNT-1. That evidence belongs to the drugs, not to Noom. Until Noom publishes an RCT showing that its coaching layer produces outcomes superior to GLP-1 alone, the behavioral component remains a differentiator by marketing claim rather than by controlled evidence.

Is Noom Legit? Regulatory and Accreditation Standing

"Legit" in the context of a telehealth weight-loss company means at least four things: legal operation, proper prescribing practices, truthful advertising, and responsible handling of patient data. Noom meets the first criterion clearly and the others with varying degrees of documented compliance.

Legal Operation and State Licensing

Noom, Inc. Is incorporated in Delaware and headquartered in New York City. Its telehealth medical subsidiary must comply with each U.S. State's telemedicine practice standards. The company has operated continuously since 2008, and no state medical board has issued a public cease-and-desist order against it as of the date of this review.

FDA and Prescribing Compliance

Noom Med prescribers operate under the same FDA rules that govern all GLP-1 prescribing. Semaglutide 2.4 mg (Wegovy) carries FDA approval for chronic weight management in adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity [5]. Tirzepatide 2.5 mg to 15 mg (Zepbound) received FDA approval in November 2023 for the same indications [6]. Prescribing these drugs within FDA-approved indications is standard medical practice.

One regulatory caution applies: the FDA has repeatedly warned against compounded semaglutide. In October 2023 and again in 2024, the FDA stated that "patients and providers should be aware of the risks associated with compounded semaglutide products, which have not been evaluated for safety, effectiveness, or quality" [7]. Some Noom Med competitors have relied on compounded versions. Noom's current formulary should be verified directly with the platform, as formulary decisions can change.

LegitScript and Pharmacy Verification

LegitScript is an independent certification body that verifies online pharmacies and telehealth providers. As of mid-2025, Noom does not appear on LegitScript's certified telehealth provider directory. This is not automatically a red flag (many legitimate platforms have not pursued certification), but it does mean no third-party has independently audited Noom's prescribing workflows.

BBB Rating and Consumer Complaints

The Better Business Bureau assigns Noom a B rating as of mid-2025, with accreditation not held. The BBB complaint portal shows a pattern of issues clustering in three areas: difficulty canceling subscriptions, unexpected charges after trial periods, and dissatisfaction with coaching quality. These are consumer-experience problems, not clinical safety violations, but they affect trust.

The FTC has broad authority over deceptive subscription practices under 15 U.S.C. § 45. Noom settled with the FTC in January 2023 for $62 million over allegations that it made it unreasonably difficult for users to cancel subscriptions and charged consumers who had attempted to cancel [8]. The settlement required Noom to simplify its cancellation process and refund affected users.

Noom's Behavioral Model: CBT Claims and Their Evidence Base

Noom markets its program as "psychology-based," citing cognitive-behavioral therapy (CBT) principles. This claim deserves a precise reading.

What CBT for Obesity Actually Requires

CBT for obesity, as described in the 2013 American Heart Association scientific statement on lifestyle interventions, involves structured sessions with a trained therapist, cognitive restructuring exercises, and behavioral monitoring [9]. A 2020 Cochrane review of behavioral interventions for obesity found that therapist-delivered CBT produced 2.0 to 4.3 kg greater weight loss than minimal interventions at 12 months [10].

How Noom's Model Compares

Noom's app delivers daily lessons drawing on CBT concepts, including self-monitoring, stimulus control, and cognitive restructuring exercises. These are legitimate CBT techniques. The delivery mechanism is asynchronous and app-based, which is a meaningful departure from therapist-delivered CBT. Noom coaches provide motivational support but are not credentialed therapists. The behavioral tools are real; the clinical intensity is lower than traditional CBT delivery.

Does Lower Intensity Still Work?

Digitally delivered behavioral interventions can produce modest but real effects. A 2021 meta-analysis in JMIR mHealth and uHealth of 14 RCTs (N=2,214) found that smartphone-based weight loss apps produced a mean additional weight loss of 1.7 kg versus control at 12 months [11]. That effect is clinically meaningful for some patients and insufficient for others. When paired with a GLP-1 agonist producing 15 to 21% weight loss, the incremental behavioral contribution is harder to isolate.

Noom Med: How the GLP-1 Program Works

Noom Med is Noom's medication-enabled weight loss tier. Understanding how it operates clinically is necessary for evaluating whether the platform is appropriate for a given patient.

Patient Intake and Physician Review

Prospective Noom Med patients complete an online health questionnaire covering medical history, current medications, and weight history. A U.S.-licensed physician reviews this intake form asynchronously, typically within 24 to 48 hours. If the patient meets FDA-approved prescribing criteria, a prescription is issued to a partner pharmacy.

No live video or phone consultation is required under Noom's standard workflow. Some patients may receive a follow-up message from a physician; others may not. This level of clinical contact is lower than what a traditional obesity medicine specialist would provide.

Monitoring and Follow-Up

After prescription issuance, Noom Med patients receive check-in prompts through the app. Clinical monitoring, including lab work such as HbA1c, thyroid panels, or lipid panels, is not built into the standard Noom Med workflow as of 2024 public disclosures. Patients with diabetes or thyroid disease may need coordination with a primary care provider to ensure appropriate monitoring. The American Association of Clinical Endocrinology (AACE) 2023 guidelines on obesity management recommend periodic metabolic monitoring every 3 to 6 months for patients on anti-obesity medications [12].

Prescription Costs and Insurance

GLP-1 medications are expensive. Wegovy lists at approximately $1,349 per month without insurance. Noom Med charges a separate subscription fee on top of pharmacy costs. Insurance coverage for Wegovy and Zepbound remains inconsistent; many commercial plans exclude anti-obesity medications. Patients should confirm coverage before enrolling.

Noom Complaints: A Structured Look

Consumer complaints about Noom fall into distinct categories. Separating clinical complaints from billing complaints matters when assessing whether Noom is safe versus whether it is consumer-friendly.

Billing and Cancellation

The most common complaint type, and the one that attracted FTC action, involves billing practices. The $62 million FTC settlement in 2023 is the largest documented regulatory action against Noom [8]. Post-settlement, Noom revised its cancellation interface, but user reviews on the BBB and app stores continued to cite billing confusion through 2024.

Coaching Quality

A subset of complaints concerns coaching responsiveness and quality. Users report inconsistent coach availability, generic responses, and high coach turnover. These are operational problems that affect user experience but do not constitute clinical harm.

Clinical Safety Reports

Public databases including the FDA's MedWatch system and the FTC complaint portal do not show a pattern of serious adverse events specifically attributed to Noom's prescribing practices as of mid-2025. This is a limited reassurance because underreporting of telehealth adverse events is well-documented.

How Noom Compares to Clinical Obesity Medicine Standards

The Obesity Medicine Association defines comprehensive obesity care as including medical history, physical examination, laboratory assessment, dietary counseling, behavioral therapy, and pharmacotherapy when indicated [13]. Noom meets some of these criteria partially:

• Medical history: collected via intake form (asynchronous, no exam)
• Physical examination: not conducted
• Laboratory assessment: not standard in the platform workflow
• Dietary counseling: app-based, non-dietitian coaches
• Behavioral therapy: CBT-informed app lessons, not therapist-delivered
• Pharmacotherapy: available through Noom Med for qualifying patients

Patients who need comprehensive obesity medicine care should consider whether a platform-only approach is sufficient. For patients who are otherwise healthy, meet FDA criteria for GLP-1 therapy, and want low-cost access to medication plus behavioral support, Noom Med may be an appropriate entry point, with the understanding that it is not a substitute for in-person metabolic evaluation.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states: "We recommend that pharmacotherapy be used as part of a comprehensive obesity treatment program that also includes behavioral therapy and lifestyle intervention" [14]. Noom's combination of app-based behavior support and medication access aligns with this framework in structure, though the clinical depth of each component is lower than what a specialist practice would deliver.